Of all the reasons that customers purchase health insurance, the risk of cancer is very often the primary driver. And for most health funds around the world, cancer is the most significant claims line, if not for cost, then for its emotional significance.
iFHP’s first study tour of 2024 will take members to the heart of what is driving the latest cancer therapies. From the latest in cancer genomics to precision therapies, immunotherapies, epigenetics, prevention and early detection, the tour will bring you to the cross roads where future cancer science and real-world funding meet. Join us in March 2024 for what promises to be an unmissable journey into the future of cancer.